Optomed Q1: Initial take – Softer sales than expected, but EBIT in line - Redeye

Redeye notes that Q1 sales were slightly lower than our estimates; however, EBIT aligned with our forecast. Furthermore, we will release a research update where we will dig deeper into the report and last week’s major milestone: the FDA clearance of Aurora AEYE.

Länk till analysen i sin helhet: https://www.redeye.se/research/1003649/optomed-q1-initial-take-softer-sales-than-expected-but-ebit-in-line?utm_source=finwire&utm_medium=RSS